Coherus BioSciences (CHRS) Defended at Citi, Analyst Says Buy Weakness - Bloomberg
- Wall Street falls with financials, other post-election gainers
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
- After-Hours Stock Movers 01/17: (SHLO) Higher; (GIMO) (AFAM) (CSX) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Coherus BioSciences (NASDAQ: CHRS) Defended at Citi, Analyst Says Buy Weakness - Bloomberg
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citigroup (C) call put ratio 3.5 calls for 1 put into Q4 and outlook
- Deutsche Bank Starts Bruker (BRKR) at Hold
- Cowen Raises Price Target on GigOptix (GIG) to $4 Following 4Q Pre-announcement
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!